On-Demand version of the April 25, 2019 eCast.
Please note: This is a Single Viewer On-Demand eCast available for one registrant to access the on-demand version of the eCast. Once registered, access is granted via the AABB Education Website located at https://education.aabb.org.
Program Description: Obstetric hemorrhage is one of the leading, and most treatable, causes of maternal morbidity and mortality worldwide. Obstetric hemorrhage accounts for more than 27% of maternal deaths worldwide, with the majority being a result of postpartum hemorrhage. Anti-fibrinolytic agents have been widely used to reduce blood loss in non-obstetric surgical cases as well as traumatic injuries and have been proposed as a treatment for post-partum hemorrhage. A multinational group of investigators recently performed a randomized, double-blinded placebo controlled trial of over 20,000 women looking at the effects of administration of 1 gram of intravenous tranexamic acid (TXA) as a potential candidate to treat post-partum hemorrhage.